K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients

The guidelines proposed by the Kidney Disease Outcomes Quality Initiative (K/DOQI) suggested that intact parathyroid hormone (iPTH) should be maintained in a target range between 150 and 300 pg ml−1 for patients with stage 5 chronic kidney disease. Our study sought to verify the effectiveness of tha...

Full description

Saved in:

Bibliographic Details
Published in:	Kidney international Vol. 73; no. 6; pp. 771 - 777
Main Authors:	Barreto, F.C., Barreto, D.V., Moysés, R.M.A., Neves, K.R., Canziani, M.E.F., Draibe, S.A., Jorgetti, V., Carvalho, A.B.
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01-03-2008 Elsevier Limited
Subjects:	Acetates - therapeutic use Adult Biopsy Bone Remodeling Brazil Calcium Compounds - therapeutic use Chelating Agents - therapeutic use Chronic Disease Chronic Kidney Disease-Mineral and Bone Disorder - diagnosis Chronic Kidney Disease-Mineral and Bone Disorder - pathology Chronic Kidney Disease-Mineral and Bone Disorder - prevention & control Female hemodialysis Humans intact PTH K/DOQI guidelines Kidney Diseases - blood Kidney Diseases - drug therapy Kidney Diseases - pathology low-turnover bone disease Male Middle Aged Parathyroid Hormone - blood Parathyroid Hormone - standards Polyamines - therapeutic use Practice Guidelines as Topic Prospective Studies Reference Values Renal Dialysis - adverse effects Sevelamer hemodialysis intact PTH low-turnover bone disease K/DOQI guidelines
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!